3-oxo-5alpha-steroid 4-dehydrogenase (NADP+) | 37255-34-8

• 分子结构分类: 氧化还原酶 - 作用于CH-CH供体
• 英文名称: 3-oxo-5alpha-steroid 4-dehydrogenase (NADP+)
• 英文别名: cholestenone 5alpha-reductase；testosterone Delta4-5alpha-reductase；steroid 5alpha-reductase；3-oxosteroid Delta4-dehydrogenase；5alpha-reductase；steroid 5alpha-hydrogenase；3-oxosteroid 5alpha-reductase；testosterone Delta4-hydrogenase；4-ene-3-oxosteroid 5alpha-reductase；reduced nicotinamide adenine dinucleotide phosphate:Delta4-3-ketosteroid 5alpha-oxidoreductase；4-ene-5alpha-reductase；Delta4-3-ketosteroid 5alpha-oxidoreductase；cholest-4-en-3-one 5alpha-reductase；testosterone 5alpha-reductase；3-oxo-5alpha-steroid 4-dehydrogenase；human prostatic 5-α-reductase
• CAS: 37255-34-8；9029-09-8；72412-84-1

反应信息

• 作为试剂：
  描述：

  睾酮 在 3-oxo-5alpha-steroid 4-dehydrogenase (NADP+) glucose-6-phosphate dehydrogenase 、 Α-D-吡喃葡萄糖6-磷酸 、 烟酰胺腺嘌呤双核苷酸磷酸盐 作用下， 反应 0.5h， 生成 雄诺龙
  参考文献：
  名称：

  Comparative study of human steroid 5α-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride

  摘要：

  Steroid 5alpha-reductase (5-AR) catalyses the reduction of testosterone (T) to dihydrotestosterone (DHT). The 5alpha-reductase found in human benign prostatic hyperplasia (BPH) has been compared with that found in human breast skin tissue in respect of sensitivity to inhibition by Finasteiide and Epristeride. Kinetic studies showed the presence of two isoforms of 5alpha-reductase in benign prostatic hyperplasia indicated by low and high Km isoforms for testosterone, while female breast skin tissue contained only one isoform. The isoforms differ in their affinity for the inhibitors Finasteride and Epristeride, both compounds being more effective for the low Km 5alpha-reductase isoform than the high Km 5alpha-reductase of prostatic tissue, with Finasteride displaying competitive inhibition and Epristeride uncompetitive. Finasteride and Epristeride are also inhibitors of skin 5alpha-reductase, which possesses a comparable Ki for Finasteride to that of the low Km prostatic enzyme, but Epristeride was a less potent inhibitor of the skin enzyme relative to the prostate isoform. These results suggest that the inhibitors have therapeutic potential, other than for treatment of benign prostatic hyperplasia, for treating skin disorders influenced by the action of dihydrotestosterone and warrant further investigation. (C) 2002 Published by Elsevier Science Inc.

  DOI：

  10.1016/s0024-3205(02)01627-2